Oragenics, Inc. to Host Webinar Panel on Neurotrauma Medicine
May 17, 2024 08:00 ET
|
Oragenics
SARASOTA, Fla., May 17, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today...
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial
May 16, 2024 08:00 ET
|
Oragenics
SARASOTA, Fla., May 16, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneering pharmaceutical company specializing in intranasal treatments for neurological disorders, today...
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
May 15, 2024 08:30 ET
|
PaxMedica, Inc.
TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the “Company” or “PaxMedica”) (OTC:PXMD), a biopharmaceutical company dedicated to advancing treatments for...
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
May 07, 2024 08:30 ET
|
PaxMedica, Inc.
TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a...
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia
May 07, 2024 08:00 ET
|
Oragenics
SARASOTA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a pioneer in developing innovative intranasal pharmaceuticals for neurological disorders, today announced a...
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
April 16, 2024 16:30 ET
|
PaxMedica, Inc.
Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates immediate need for direct access to the global drug market for affected nationsAs previously...
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
March 13, 2024 08:20 ET
|
PaxMedica, Inc.
TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today...
NeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13
February 08, 2024 15:30 ET
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., Feb. 08, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...
Deep Brain Stimulation Devices Market to Witness USD 3.5 Billion Expansion by 2033, Driven by Surging Demand and Ongoing Research Advancements
January 11, 2024 06:55 ET
|
Market.Us
New York, Jan. 11, 2024 (GLOBE NEWSWIRE) -- According to market.us, the Deep Brain Stimulation Devices Market is expected to reach around USD 3.5 Billion by 2033, indicating substantial growth...
PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial Data
November 17, 2023 08:00 ET
|
PaxMedica, Inc.
LOS ANGELES, Nov. 17, 2023 (GLOBE NEWSWIRE) -- via IBN –PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announces that...